Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 12/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14160038 | 0.88 | SIGMAR1 (0.40) | GPR6HRH3CHRM4MAOAMAOB | |
| SCHEMBL14159981 | 0.87 | USP14 (0.38) | GPR6HRH3CHRM4MAOAMAOB | |
| SCHEMBL3601137 | 0.87 | GPR6 (0.35) | GPR6HRH3CHRM4 | |
| SCHEMBL3589024 | 0.85 | GPR6 (0.34) | GPR6HRH3CHRM4 | |
| SCHEMBL3595718 | 0.85 | GPR6 (0.35) | GPR6HRH3CHRM4 | |
| SCHEMBL3595378 | 0.83 | GPR6 (0.34) | GPR6HRH3 | |
| SCHEMBL3594452 | 0.83 | GPR6 (0.34) | GPR6 | |
| SCHEMBL3589355 | 0.81 | GPR6 (0.35) | GPR6HRH3CHRM4 | |
| SCHEMBL3592879 | 0.78 | HRH3 (0.44) | HRH3MAOAMAOB | |
| SCHEMBL13254371 | 0.77 | SIGMAR1 (0.40) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | GPR6 154/4885HRH3 832/4885CHRM4 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.